Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

BACKGROUND: Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson’s disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CNS Drugs
Egile Nagusiak: Elmer, Lawrence W., Juncos, Jorge L., Singer, Carlos, Truong, Daniel D., Criswell, Susan R., Parashos, Sotirios, Felt, Larissa, Johnson, Reed, Patni, Rajiv
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2018
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934466/
https://ncbi.nlm.nih.gov/pubmed/29532440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-018-0498-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak